Although recent studies have shown a significant association between the response to cetuximab treatment and EGFR amplification or K-ras mutations in colorectal cancer, none of the patients in the present study exhibited increased EGFR gene copy number (EGFR/CEP7 >2.0) or K-ras mutations. This evidence concerns the gene KRAS and colorectal cancer.